135 related articles for article (PubMed ID: 8181857)
21. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
[TBL] [Abstract][Full Text] [Related]
22. Antigenic variation in cancer metastasis: immune escape versus immune control.
Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
[TBL] [Abstract][Full Text] [Related]
23. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.
Schirrmacher V; Müerköster S; Umansky V
Clin Cancer Res; 1998 Nov; 4(11):2635-45. PubMed ID: 9829726
[TBL] [Abstract][Full Text] [Related]
24. Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.
Colombo MP; Arioli I; Parmiani G
Int J Cancer; 1984 Dec; 34(6):807-13. PubMed ID: 6334656
[TBL] [Abstract][Full Text] [Related]
25. A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo.
Umansky V; Beckhove P; Rocha M; Krüger A; Crocker PR; Schirrmacher V
Immunology; 1996 Feb; 87(2):303-9. PubMed ID: 8698395
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
[TBL] [Abstract][Full Text] [Related]
27. Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice.
Denkers EY; Gazzinelli RT; Martin D; Sher A
J Exp Med; 1993 Nov; 178(5):1465-72. PubMed ID: 8228800
[TBL] [Abstract][Full Text] [Related]
28. Expression of Ia antigens in a murine T-lymphoma variant.
Graf L; Koch N; Schirrmacher V
Mol Immunol; 1985 Dec; 22(12):1371-7. PubMed ID: 3938525
[TBL] [Abstract][Full Text] [Related]
29. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice.
Schirrmacher V
Int J Cancer; 1979 Jul; 24(1):80-6. PubMed ID: 314423
[No Abstract] [Full Text] [Related]
30. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer.
Schiavoni G; Mattei F; Di Pucchio T; Santini SM; Bracci L; Belardelli F; Proietti E
Blood; 2000 Mar; 95(6):2024-30. PubMed ID: 10706870
[TBL] [Abstract][Full Text] [Related]
32. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
[TBL] [Abstract][Full Text] [Related]
33. Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
Dennis JW; Laferté S; Man MS; Elliott BE; Kerbel RS
Int J Cancer; 1984 Nov; 34(5):709-16. PubMed ID: 6437992
[TBL] [Abstract][Full Text] [Related]
34. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
[TBL] [Abstract][Full Text] [Related]
35. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
Von Hoegen P; Weber E; Schirrmacher V
Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
[TBL] [Abstract][Full Text] [Related]
36. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells.
Gresser I; Maury C; Woodrow D; Moss J; Grütter MG; Vignaux F; Belardelli F; Maunoury MT
Int J Cancer; 1988 Jan; 41(1):135-42. PubMed ID: 3422071
[TBL] [Abstract][Full Text] [Related]
37. Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo.
Jurianz K; von Hoegen P; Schirrmacher V
Int J Oncol; 1999 Jul; 15(1):71-9. PubMed ID: 10375596
[TBL] [Abstract][Full Text] [Related]
38. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
Wehrmaker A; Lehmann V; Dröge W
Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
[TBL] [Abstract][Full Text] [Related]
39. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.
Christianson SW; Shultz LD; Leiter EH
Diabetes; 1993 Jan; 42(1):44-55. PubMed ID: 8093606
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
Ehrke MJ; Verstovsek S; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Mihich E
Int J Cancer; 1995 Nov; 63(3):463-71. PubMed ID: 7591249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
